FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Seibold

Research Profile

Disorders

Concepts & Ideas

Procedures

Anatomy

Skin
Fingers

Chemicals & Drugs

Activities & Behaviors

Questionnaires

Co-author Network

Publications

TOP 3
Emily W Hung; Lynette Keyes-Elstein; Dinesh Khanna; Sharon Leclercq; Victor I Machicao; MD Mayes; Peter McSweeney; Shin Mineishi; Richard A Nash; Kristine Phillips; James R Seibold; Roozbeh Sharif; Robert W Simms; E William St Clair; Jan Storek; Shervin Assassi; Karen Ballen; Christopher N Bredeson; Sharon Castina; Leslie J Crofford; Mary Ellen Csuka; Stephen Forman; Daniel E Furst; Ellen Goldmuntz; Chitra Hosing; Beverly Welch; Mark H Wener; Keith M Sullivan
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.
Peter A Merkel; R P Polisson; J E Pope; James R Seibold; N P Silliman; James B Streisand; Philip J Clements; Christopher P Denton; Daniel E Furst; MD Mayes
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Pei-Suen Tsou; Sergio A Jimenez; Ann Kendzicky; Kristine Phillips; Sonsoles Piera-Velazquez; Adam J Pinney; James R Seibold; Nadine N Talia; Alisa E Koch
Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Seibold (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emily W Hung; Lynette Keyes-Elstein; Dinesh Khanna; Sharon Leclercq; Victor I Machicao; MD Mayes; Peter McSweeney; Shin Mineishi; Richard A Nash; Kristine Phillips; James R Seibold; Roozbeh Sharif; Robert W Simms; E William St Clair; Jan Storek; Shervin Assassi; Karen Ballen; Christopher N Bredeson; Sharon Castina; Leslie J Crofford; Mary Ellen Csuka; Stephen Forman; Daniel E Furst; Ellen Goldmuntz; Chitra Hosing; Beverly Welch; Mark H Wener; Keith M Sullivan
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.
The Journal of rheumatology 2013;40(4):455-60.
2012: Peter A Merkel; R P Polisson; J E Pope; James R Seibold; N P Silliman; James B Streisand; Philip J Clements; Christopher P Denton; Daniel E Furst; MD Mayes
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Arthritis and rheumatism 2012;64(10):3420-9.
2012: Pei-Suen Tsou; Sergio A Jimenez; Ann Kendzicky; Kristine Phillips; Sonsoles Piera-Velazquez; Adam J Pinney; James R Seibold; Nadine N Talia; Alisa E Koch
Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.
Arthritis and rheumatism 2012;64(6):1978-89.
2011: Dinesh Khanna; Michael D Roth; Rajan Saggar; James R Seibold; Virginia Steen; Philip J Clements; Robert Elashoff; Niloofar Farmani; Daniel E Furst; Jonathan Goldin; Chi-Hong Tseng; Donald P Tashkin
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.
Arthritis and rheumatism 2011;63(10):3078-85.
2011: Dinesh Khanna; Paul Maranian; MD Mayes; James R Seibold; Philip J Clements; Daniel E Furst; Terri Getzug; ann impens; Ron D Hays
Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
The Journal of rheumatology 2011;38(9):1920-4.
2011: Mahsa Nashid; Puja P Khanna; Daniel E Furst; Philip J Clements; Paul Maranian; James R Seibold; Arnold E Postlethwaite; James S Louie; MD Mayes; Harsh Agrawal; Dinesh Khanna
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials.
Rheumatology (Oxford, England) 2011;50(2):335-42.
2011: Vijay Bodukam; Ron D Hays; Paul Maranian; Daniel E Furst; James R Seibold; ann impens; MD Mayes; Philip J Clements; Dinesh Khanna
Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
Rheumatology (Oxford, England) 2011;50(2):330-4.
2011: Bradley J Rabquer; James R Seibold; Eshwar Thirunavukkarasu; Pei-Suen Tsou; G Kenneth Haines; Yong Hou; Ann J Impens; Bashar Kahaleh; Kristine Phillips; Alisa E Koch
Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.
Arthritis research & therapy 2011;13(1):R18.
2011: Marco Matucci-Cerinic; Christopher P Denton; Daniel E Furst; Maureen D Mayes; Vivien M Hsu; Patrick Carpentier; Fredrick M Wigley; Carol M Black; Barri J Fessler; Peter A Merkel; Janet E Pope; Nadera Sweiss; Mittie K Doyle; Bernhard Hellmich; Thomas A Medsger; Adele Morganti; Fabrice Kramer; Joseph H Korn; James R Seibold
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Annals of the rheumatic diseases 2011;70(1):32-8.
2010: Jérôme Avouac; Otylia Kowal-Bielecka; David Pittrow; Doerte Huscher; Frank Behrens; Christopher P Denton; Ivan Foeldvari; Marc Humbert; Marco Matucci-Cerinic; Peter Nash; Christian F Opitz; Lewis J Rubin; James R Seibold; Oliver Distler; Daniel E Furst
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group.
Annals of the rheumatic diseases 2010;69(7):1360-3.
2010: Dinesh Khanna; Kevin K Brown; Philip J Clements; Robert Elashoff; Daniel E Furst; Jonathan Goldin; James R Seibold; Richard M Silver; Donald P Tashkin; Athol U Wells
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
Clinical and experimental rheumatology 2010;28(2 Suppl 58):S55-62.
2010: ann impens; James R Seibold
Vascular alterations and sexual function in systemic sclerosis.
International journal of rheumatology 2010;2010():139020.
2010: Otylia Kowal-Bielecka; Jerome Avouac; David Pittrow; Doerte Huscher; Frank Behrens; Christopher P Denton; Ivan Foeldvari; Marc Humbert; Marco Matucci-Cerinic; Peter Nash; Christian F Opitz; Lewis J Rubin; James R Seibold; Vibeke Strand; Daniel E Furst; Oliver Distler
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.
The Journal of rheumatology 2010;37(1):105-15.
2010: Y Hou; B J Rabquer; M L Gerber; F Del Galdo; S A Jimenez; G K Haines; W G Barr; M C Massa; James R Seibold; Alisa E Koch
Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion.
Annals of the rheumatic diseases 2010;69(1):249-54.
2009: Dinesh Khanna; Oliver Distler; Jerome Avouac; Frank Behrens; Philip J Clements; Christopher Denton; Ivan Foeldvari; Edward Giannini; Doerte Huscher; Otylia Kowal-Bielecka; Daniel Lovell; Marco Matucci-Cerinic; MD Mayes; Peter A Merkel; Peter Nash; Christian F Opitz; David Pittrow; Lewis Rubin; James R Seibold; Virginia D Steen; C Vibeke Strand; Peter S Tugwell; John Varga; Angela Zink; Daniel E Furst
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
The Journal of rheumatology 2009;36(10):2356-61.
2009: Elena Schiopu; Vivien M Hsu; ann impens; Jennifer A Rothman; Deborah A McCloskey; Julianne E Wilson; Kristine Phillips; James R Seibold
Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
The Journal of rheumatology 2009;36(10):2264-8.
2009: Dinesh Khanna; Ron D Hays; Paul Maranian; James R Seibold; ann impens; MD Mayes; Philip J Clements; Terri Getzug; Nihal Fathi; Amber Bechtel; Daniel E Furst
Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Arthritis and rheumatism 2009;61(9):1257-63.
2009: Marian Kaldas; Puja P Khanna; Daniel E Furst; Philip J Clements; Weng Kee Wong; James R Seibold; Arnold E Postlethwaite; Dinesh Khanna
Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
Rheumatology (Oxford, England) 2009;48(9):1143-6.
2009: Bradley J Rabquer; Yong Hou; francesco del galdo; G Kenneth Haines; Michele L Gerber; Sergio A Jimenez; James R Seibold; Alisa E Koch
The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1.
Rheumatology (Oxford, England) 2009;48(7):734-40.
2009: ann impens; J Rothman; E Schiopu; J C Cole; J Dang; N Gendrano; R C Rosen; James R Seibold
Sexual activity and functioning in female scleroderma patients.
Clinical and experimental rheumatology 2009;27(3 Suppl 54):38-43.
2009: Philip J Clements; Marco Matucci-Cerinic; S Bombardieri; James R Seibold
A world of progress in systemic sclerosis.
Clinical and experimental rheumatology 2009;27(3 Suppl 54):1.
2009: Kristine Phillips; Cathryn Byrne-Dugan; Eric Batterson; James R Seibold
Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis.
Nature reviews. Rheumatology 2009;5(4):225-8.
2009: Dinesh Khanna; Philip J Clements; Daniel E Furst; Joseph H Korn; Michael H Ellman; Naomi F Rothfield; Fredrick M Wigley; Larry W Moreland; Richard M Silver; Youn H Kim; Virginia D Steen; Gary S Firestein; Arthur F Kavanaugh; Michael Weisman; MD Mayes; David Collier; Mary E Csuka; Robert W Simms; Peter A Merkel; Thomas A Medsger; Martin E Sanders; Paul Maranian; James R Seibold
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
Arthritis and rheumatism 2009;60(4):1102-11.
2008: ann impens; S Wangkaew; James R Seibold
The 6-minute walk test in scleroderma--how measuring everything measures nothing.
Rheumatology (Oxford, England) 2008;47 Suppl 5():v68-9.
2008: James R Seibold; A Tyndall; D E Furst
Trial design: how must we move ahead?
Rheumatology (Oxford, England) 2008;47 Suppl 5():v57-8.
2008: Marco Matucci-Cerinic; James R Seibold
Digital ulcers and outcomes assessment in scleroderma.
Rheumatology (Oxford, England) 2008;47 Suppl 5():v46-7.
2008: Oliver Distler; Marco Matucci-Cerinic; Ulf Müller-Ladner; James R Seibold
A path to the future in scleroderma.
Rheumatology (Oxford, England) 2008;47 Suppl 5():v1.
2008: Oliver Distler; Frank Behrens; David Pittrow; Doerte Huscher; Christopher P Denton; Ivan Foeldvari; Marc Humbert; Marco Matucci-Cerinic; Peter Nash; Christian F Opitz; Lewis J Rubin; James R Seibold; Daniel E Furst
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
Arthritis and rheumatism 2008;59(6):867-75.
2008: Charlton B. Strange; James R Seibold
Scleroderma lung disease: "if you don't know where you are going, any road will take you there".
American journal of respiratory and critical care medicine 2008;177(11):1178-9.
2008: Peter A Merkel; Nancy P Silliman; Christopher P Denton; Daniel E Furst; Dinesh Khanna; Paul Emery; Vivien M Hsu; James B Streisand; Richard P Polisson; Anita Akesson; John Coppock; Frank van den Hoogen; Ariane Herrick; MD Mayes; douglas veale; James R Seibold; Carol M Black; Joseph H Korn
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.
Arthritis and rheumatism 2008;59(5):699-705.
2008: Dinesh Khanna; D J Lovell; E Giannini; Philip J Clements; Peter A Merkel; James R Seibold; Marco Matucci-Cerinic; C P Denton; MD Mayes; Virginia D Steen; John Varga; Daniel E Furst
Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
Annals of the rheumatic diseases 2008;67(5):703-9.
2008: Vivien M Hsu; Abel E Moreyra; Alan C Wilson; Meir Shinnar; Daniel M Shindler; Julianne E Wilson; Ami Desai; James R Seibold
Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.
The Journal of rheumatology 2008;35(3):458-65.
2007: Philip J Clements; Michael D Roth; Robert Elashoff; Donald P Tashkin; Jonathan G Goldin; Richard M Silver; Mildred G Sterz; James R Seibold; Dean E Schraufnagel; Robert W Simms; Marcy B Bolster; Robert Wise; Virginia Steen; MD Mayes; Kari Connelly; Mark L Metersky; Daniel E Furst
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Annals of the rheumatic diseases 2007;66(12):1641-7.
2007: Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlton B. Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick M Wigley; Barbara A White; Virginia Steen; Charles Read; MD Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
American journal of respiratory and critical care medicine 2007;176(10):1026-34.
2007: Reda E Girgis; Adaani E Frost; Nicholas S Hill; Evelyn M Horn; David Langleben; Vallerie V McLaughlin; Ronald J Oudiz; Ivan M Robbins; James R Seibold; Shelley Shapiro; Victor F Tapson; Robyn J Barst
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
Annals of the rheumatic diseases 2007;66(11):1467-72.
2007: Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer H Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona A Holmberg; Gretchen Henstorf; Charles F LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard M Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
Blood 2007;110(4):1388-96.
2007: Daniel Furst; Dinesh Khanna; Marco Matucci-Cerinic; Philip Clements; Virginia Steen; Janet Pope; Peter A Merkel; Ivan Foeldvari; James R Seibold; David Pittrow; Richard Polisson; Vibeke Strand
Systemic sclerosis - continuing progress in developing clinical measures of response.
The Journal of rheumatology 2007;34(5):1194-200.
2007: Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard M Silver; Charlton B. Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick M Wigley; Barbara A White; Virginia Steen; Charles Read; MD Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Arthritis and rheumatism 2007;56(5):1676-84.
2007: James R Seibold
Are endothelin-receptor antagonists the preferred treatment for PAH associated with scleroderma?
Nature clinical practice. Rheumatology 2007;3(4):204-5.
2007: Dinesh Khanna; G S Park; James R Seibold
SF-36 Scales in the Relaxin study.
Rheumatology (Oxford, England) 2007;46(4):724.
2007: M H Buch; C P Denton; D E Furst; L Guillevin; Lewis J Rubin; A U Wells; M Matucci-Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black; James R Seibold
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.
Annals of the rheumatic diseases 2007;66(2):169-73.
2007: Marco Matucci-Cerinic; Virginia D Steen; Daniel E Furst; James R Seibold
Clinical trials in systemic sclerosis: lessons learned and outcomes.
Arthritis research & therapy 2007;9 Suppl 2():S7.
2007: Lewis J Rubin; Carol M Black; Christopher P Denton; James R Seibold
Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease.
Arthritis research & therapy 2007;9 Suppl 2():S10.
2007: Christopher P Denton; Peter A Merkel; Daniel E Furst; Dinesh Khanna; Paul Emery; Vivien M Hsu; Nancy Silliman; James Streisand; John Powell; Anita Akesson; John Coppock; Frank van den Hoogen; Ariane Herrick; MD Mayes; douglas veale; Joanna Haas; Stephen Ledbetter; Joseph H Korn; Carol M Black; James R Seibold
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Arthritis and rheumatism 2007;56(1):323-33.
2006: O Distler; Frank Behrens; Doerte Huscher; Ivan Foeldvari; Angela Zink; P Nash; C P Denton; M Humbert; Marco Matucci-Cerinic; James R Seibold; Lewis J Rubin; D E Furst
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis.
Rheumatology (Oxford, England) 2006;45(12):1455-7.
2006: Jason C Cole; Dinesh Khanna; Philip J Clements; James R Seibold; Donald P Tashkin; Harold E Paulus; Michael R Irwin; Sarosh J Motivala; Daniel E Furst
Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2006;15(8):1383-94.
2006: Dinesh Khanna; Daniel E Furst; Ron Hays; Grace S Park; Weng Kee Wong; James R Seibold; MD Mayes; Barbara A White; Fredrick M Wigley; Michael Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
Annals of the rheumatic diseases 2006;65(10):1325-9.
2006: Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard M Silver; Charlton B. Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick M Wigley; Barbara A White; Virginia Steen; Charles Read; MD Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Cyclophosphamide versus placebo in scleroderma lung disease.
The New England journal of medicine 2006;354(25):2655-66.
2006: Amit Joglekar; Fausan S Tsai; Deborah A McCloskey; Julianne E Wilson; James R Seibold; David J Riley
Bosentan in pulmonary arterial hypertension secondary to scleroderma.
The Journal of rheumatology 2006;33(1):61-8.
2005: Dinesh Khanna; Daniel E Furst; Philip J Clements; Grace S Park; Ron Hays; Jeonglim Yoon; Joseph H Korn; Peter A Merkel; Naomi F Rothfield; Fredrick M Wigley; Larry W Moreland; Richard M Silver; Virginia Steen; Michael Weisman; MD Mayes; David H Collier; Thomas A Medsger; James R Seibold
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
The Journal of rheumatology 2005;32(5):832-40.
2005: Dinesh Khanna; Philip J Clements; Daniel E Furst; Yun Chon; Robert Elashoff; Michael D Roth; Mildred G Sterz; Joannie Chung; John D FitzGerald; James R Seibold; John Varga; Arthur Theodore; Fredrick M Wigley; Richard M Silver; Virginia Steen; MD Mayes; M Kari Connolly; Barri J Fessler; Naomi F Rothfield; Kamal Mubarak; Jerry Molitor; Donald P Tashkin
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Arthritis and rheumatism 2005;52(2):592-600.
2005: Sergio Generini; James R Seibold; Marco Matucci-Cerinic
Estrogens and neuropeptides in Raynaud's phenomenon.
Rheumatic diseases clinics of North America 2005;31(1):177-86, x-xi.
2004: Joseph H Korn; MD Mayes; marco matucci cerinic; Maurizio Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; James R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; Ariane Herrick; Peter A Merkel; Robert W Simms; Christopher P Denton; Daniel E Furst; N Nguyen; M Gaitonde; Carol Black
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Arthritis and rheumatism 2004;50(12):3985-93.
2004: Paul Hong; Janet E Pope; Janine M Ouimet; Eugenia Rullan; James R Seibold
Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis.
The Journal of rheumatology 2004;31(3):508-13.
2004: Philip J Clements; James R Seibold; Daniel E Furst; MD Mayes; Barbara A White; Fredrick M Wigley; Michael D Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Weng Kee Wong
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
Seminars in arthritis and rheumatism 2004;33(4):249-63.
2003: Anita Akesson; G Fiori; T Krieg; F H van den Hoogen; James R Seibold
Assessment of skin, joint, tendon and muscle involvement.
Clinical and experimental rheumatology 2003;21(3 Suppl 29):S5-8.
2002: Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; MD Mayes; Barbara A White; Fredrick M Wigley; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
Arthritis and rheumatism 2002;46(11):2983-9.
2002: Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; MD Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara A White; James R Seibold; Fredrick M Wigley
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Arthritis and rheumatism 2002;46(9):2410-20.
2002: James R Seibold
Relaxins: lessons and limitations.
Current rheumatology reports 2002;4(4):275-6.
2001: James R Seibold
Clinical trials: types, design, and end-points.
Current opinion in rheumatology 2001;13(6):512-5.
2001: Daniel E Furst; Philip J Clements; W K Wong; MD Mayes; Fredrick M Wigley; Barbara A White; Michael Weisman; W Barr; Larry Moreland; R Martin; Thomas A Medsger; Virginia Steen; D Collier; A Weinstein; Edward Lally; J Varga; Steven R Weiner; B Andrews; Micha Abeles; J B Peter; James R Seibold
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial.
Rheumatology (Oxford, England) 2001;40(6):615-22.
2001: Janet E Pope; Nicholas Bellamy; James R Seibold; Murray Baron; Michael H Ellman; S Carette; C D Smith; I M Chalmers; Paul Hong; D O'Hanlon; E Kaminska; J Markland; J Sibley; Luis Catoggio; Daniel E Furst
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Arthritis and rheumatism 2001;44(6):1351-8.
2001: Philip J Clements; Weng Kee Wong; Eric L Hurwitz; Daniel E Furst; MD Mayes; Barbara A White; Fredrick M Wigley; Michael Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; James R Seibold
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Arthritis and rheumatism 2001;44(3):653-61.
2000: Philip J Clements; Eric L Hurwitz; Weng Kee Wong; James R Seibold; MD Mayes; Barbara A White; Fredrick M Wigley; Michael Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Daniel E Furst
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Arthritis and rheumatism 2000;43(11):2445-54.
2000: James R Seibold; Joseph H Korn; Robert W Simms; Philip J Clements; Larry W Moreland; MD Mayes; Daniel E Furst; Naomi F Rothfield; Virginia Steen; Michael Weisman; D Collier; Fredrick M Wigley; Peter A Merkel; Mary Ellen Csuka; V Hsu; S Rocco; ME Erikson; JF Hannigan; W S Harkonen; M E Sanders
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
Annals of internal medicine 2000;132(11):871-9.
2000: Susan E Boruchoff; MG Sturgill; KW Grasing; James R Seibold; Jacqueline B McCrea; Gregory A Winchell; S E Kusma; Paul J Deutsch
The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.
Clinical pharmacology and therapeutics 2000;67(4):351-9.
1999: Philip J Clements; Weng Kee Wong; Eric L Hurwitz; Daniel E Furst; MD Mayes; Barbara A White; Fredrick M Wigley; Michael Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; R Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; S Weiner; Brian Andrews; Micha Abeles; James R Seibold
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Arthritis and rheumatism 1999;42(11):2372-80.
1999: MG Sturgill; James R Seibold; Susan E Boruchoff; Kuang C Yeh; HM Haddix; Paul J Deutsch
Trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir.
Journal of clinical pharmacology 1999;39(10):1077-84.
1999: S Dash; James R Seibold; ML Tiku
Successful treatment of methotrexate induced nodulosis with D-penicillamine.
The Journal of rheumatology 1999;26(6):1396-9.
1999: Philip J Clements; Daniel E Furst; Weng Kee Wong; MD Mayes; Barbara A White; Fredrick M Wigley; Michael H Weisman; Water Barr; L W Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; S Weiner; Brian Andrews; Micha Abeles; James R Seibold
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Arthritis and rheumatism 1999;42(6):1194-203.
1999: Janet E Pope; James R Seibold
International Conference on Systemic Sclerosis.
The Journal of rheumatology 1999;26(4):938-44.
1999: Elliot W Ehrich; aimee dallob; Inge De Lepeleire; Anne Van Hecken; D Riendeau; W Yuan; Arturo G Porras; JM Wittreich; James R Seibold; Paul De Schepper; D R Mehlisch; Barry J Gertz
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Clinical pharmacology and therapeutics 1999;65(3):336-47.
1998: MG Sturgill; James R Seibold
Rational use of calcium-channel antagonists in Raynaud's phenomenon.
Current opinion in rheumatology 1998;10(6):584-8.
1998: Fredrick M Wigley; Joseph H Korn; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; R Martin; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jimenez; MD Mayes; Peter A Merkel; B Gruber; L Kaufman; John Varga; P Bell; J Kern; P Marrott; Barbara A White; Robert W Simms; A C Phillips; James R Seibold
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Arthritis and rheumatism 1998;41(4):670-7.
1998: James R Seibold; Philip J Clements; Daniel E Furst; MD Mayes; Deborah A McCloskey; Larry W Moreland; Barbara A White; Fredrick M Wigley; S Rocco; ME Erikson; JF Hannigan; M E Sanders; E P Amento
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis.
The Journal of rheumatology 1998;25(2):302-7.
1998: D E Furst; Philip J Clements; Virginia Steen; Thomas A Medsger; Alfonse Thomas Masi; W A D'Angelo; P A Lachenbruch; R G Grau; James R Seibold
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.
The Journal of rheumatology 1998;25(1):84-8.
1997: James R Seibold; Deborah A McCloskey
Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis.
Current opinion in rheumatology 1997;9(6):571-5.
1997: Daniel Salazar; D R Much; PS Nichola; James R Seibold; D Shindler; P H Slugg
A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects.
Journal of clinical pharmacology 1997;37(9):799-809.
1997: MG Sturgill; KW Grasing; Raymond C Rosen; Thekkumkat John Thomas; G D Kulkarni; J R Trout; M Maines; James R Seibold
Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior.
Journal of cardiovascular pharmacology 1997;29(6):697-703.
1997: Susan E Kirk; Barry J Gertz; S H Schneider; Mark L Hartman; Suzan S Pezzoli; JM Wittreich; David Krupa; James R Seibold; Michael O Thorner
Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men.
The Journal of clinical endocrinology and metabolism 1997;82(4):1154-9.
1997: Ellen C Ebert; F M Ruggiero; James R Seibold
Intestinal perforation. A common complication of scleroderma.
Digestive diseases and sciences 1997;42(3):549-53.
1996: KW Grasing; MG Sturgill; Raymond C Rosen; J R Trout; Thekkumkat John Thomas; G D Kulkarni; P Maines; James R Seibold
Effects of yohimbine on autonomic measures are determined by individual values for area under the concentration-time curve.
Journal of clinical pharmacology 1996;36(9):814-22.
1996: KW Grasing; M G Murphy; J Lin; M Swigar; D Freedholm; L Clarke; J Zhang; Owen Wolkowitz; H Weingartner; K Putnam; James R Seibold
Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonist.
Journal of clinical pharmacology 1996;36(4):292-300.
1996: KW Grasing; D Freedholm; M G Murphy; M Swigar; T Russer; J Nosher; J Lin; V Frame; L Clarke; James R Seibold
Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humans.
The American journal of gastroenterology 1996;91(3):569-73.
1995: Thekkumkat John Thomas; James R Seibold; L E Adams; Evelyn V Hess
Triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine.
The Biochemical journal 1995;311 ( Pt 1)():183-8.
1995: Thekkumkat John Thomas; U B Gunnia; James R Seibold; Thresia Thomas
Defective signal-transduction pathways in T-cells from autoimmune MRL-lpr/lpr mice are associated with increased polyamine concentrations.
The Biochemical journal 1995;311 ( Pt 1)():175-82.
1995: RD Huhn; EJ Yurkow; John Kuhn; L Clarke; H Gunn; D Resta; R Shah; L A Myers; James R Seibold
Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers.
Clinical pharmacology and therapeutics 1995;57(1):32-41.
1994: H Cheng; Jules I Schwartz; C Lin; RD Amin; James R Seibold; K C Lasseter; D L Ebel; D J Tocco; John D Rogers
The bioavailability and nonlinear pharmacokinetics of MK-679 in humans.
Biopharmaceutics & drug disposition 1994;15(5):409-18.
1994: H Cheng; John D Rogers; J L Demetriades; Sherry D Holland; James R Seibold; E Depuy
Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.
Pharmaceutical research 1994;11(6):824-30.
1994: James R Seibold
Critical tissue ischaemia in scleroderma: a note of caution.
Annals of the rheumatic diseases 1994;53(5):289-90.
1994: James R Seibold; N E Allegar
The treatment of Raynaud's phenomenon.
Clinics in dermatology 1994;12(2):317-21.
1994: D E Cohen; L D Kaufman; A A Varma; James R Seibold; M Stiller; Barry L Gruber
Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to laminin.
Annals of the rheumatic diseases 1994;53(3):191-3.
1994: Fredrick M Wigley; Robert Wise; James R Seibold; D A McCloskey; G Kujala; Thomas A Medsger; Virginia D Steen; John Varga; S Jimenez; MD Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
Annals of internal medicine 1994;120(3):199-206.
1994: Jules I Schwartz; O L Laskin; C A Meeter; P M Patterson; S H Schneider; K C Lasseter; James R Seibold
Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations.
Clinical pharmacology and therapeutics 1994;55(1):50-4.
1994: Daniel O Clegg; James C Reading; MD Mayes; James R Seibold; C Harris; Fredrick M Wigley; J R Ward; E J Pisko; M H Weisman; P Lee
Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma.
The Journal of rheumatology 1994;21(1):105-10.
1994: H C Hsu; James R Seibold; Thekkumkat John Thomas
Regulation of ornithine decarboxylase in the kidney of autoimmune mice with the lpr gene.
Autoimmunity 1994;19(4):253-64.
1993: P J Clements; P A Lachenbruch; James R Seibold; B Zee; Virginia D Steen; P Brennan; A J Silman; N Allegar; J Varga; M Massa
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.
The Journal of rheumatology 1993;20(11):1892-6.
1993: Barry J Gertz; J S Barrett; R Eisenhandler; David Krupa; JM Wittreich; James R Seibold; S H Schneider
Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
The Journal of clinical endocrinology and metabolism 1993;77(5):1393-7.
1993: Thekkumkat John Thomas; James R Seibold; L E Adams; Evelyn V Hess
Hydralazine induces Z-DNA conformation in a polynucleotide and elicits anti(Z-DNA) antibodies in treated patients.
The Biochemical journal 1993;294 ( Pt 2)():419-25.
1993: Thresia Thomas; U B Gunnia; EJ Yurkow; James R Seibold; Thekkumkat John Thomas
Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells.
The Biochemical journal 1993;291 ( Pt 2)():375-81.
1993: H C Hsu; Thresia Thomas; James R Seibold; Thekkumkat John Thomas
Studies on the effects of an ornithine decarboxylase inhibitor on lupus nephritis reveal a post-transcriptional modification of the enzyme.
Agents and actions 1993;39 Spec No():C204-6.
1992: Fredrick M Wigley; James R Seibold; Robert Wise; D A McCloskey; W P Dole
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
The Journal of rheumatology 1992;19(9):1407-14.
1992: J F Fries; James R Seibold; T A Medsger
Photopheresis for scleroderma? No!
The Journal of rheumatology 1992;19(7):1011-3.
1992: James R Seibold; D E Furst; P J Clements
Why everything (or nothing) seems to work in the treatment of scleroderma.
The Journal of rheumatology 1992;19(5):673-6.
1992: MS Cappell; James R Seibold
Mesenteric thrombosis associated with anticardiolipin antibodies in a patient with systemic lupus erythematosus.
The American journal of gastroenterology 1992;87(4):520-2.
1991: H N Claman; R C Giorno; James R Seibold
Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin".
Arthritis and rheumatism 1991;34(12):1495-501.
1991: Howard Dang; M J Dauphinée; Norman Talal; Robert F Garry; James R Seibold; T A Medsger; S Alexander; C A Feghali
Serum antibody to retroviral gag proteins in systemic sclerosis.
Arthritis and rheumatism 1991;34(10):1336-7.
1991: U B Gunnia; P S Amenta; James R Seibold; Thekkumkat John Thomas
Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase.
Kidney international 1991;39(5):882-90.
1991: C L Deal; T J Schnitzer; E Lipstein; James R Seibold; R M Stevens; M D Levy; D Albert; F Renold
Treatment of arthritis with topical capsaicin: a double-blind trial.
Clinical therapeutics 1991;13(3):383-95.
1991: Thresia Thomas; U B Gunnia; James R Seibold; Thekkumkat John Thomas
Restoration of the DNA binding activity of estrogen receptor in MRL-lpr/lpr mice by a polyamine biosynthesis inhibitor.
Arthritis and rheumatism 1991;34(1):55-62.
1990: James R Seibold; R C Giorno; H N Claman
Dermal mast cell degranulation in systemic sclerosis.
Arthritis and rheumatism 1990;33(11):1702-9.
1990: A S Lichtbroun; L M Sandhaus; R C Giorno; H Kim; James R Seibold
Myocardial mast cells in systemic sclerosis: a report of three fatal cases.
The American journal of medicine 1990;89(3):372-6.
1990: M Engelhart; James R Seibold
The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon.
Angiology 1990;41(9 Pt 1):715-23.
1990: D Degiannis; James R Seibold; M Czarnecki; J Raskova; K Raska
Soluble and cellular markers of immune activation in patients with systemic sclerosis.
Clinical immunology and immunopathology 1990;56(2):259-70.
1990: M Engelhart; James R Seibold
Cyanosis and Raynaud's phenomenon: the relation to underlying disease and venous abnormalities.
Angiology 1990;41(6):432-8.
1990: D Degiannis; James R Seibold; M Czarnecki; J Raskova; K Raska
Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.
Arthritis and rheumatism 1990;33(3):375-80.
1989: Paul H Wooley; James R Seibold; JD Whalen; J M Chapdelaine
Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease.
Arthritis and rheumatism 1989;32(8):1022-30.
1989: L D Kaufman; Barry L Gruber; Mary J Marchese; James R Seibold
Anti-IgE autoantibodies in systemic sclerosis (scleroderma).
Annals of the rheumatic diseases 1989;48(3):201-5.
1988: John B Kostis; James R Seibold; D Turkevich; Alfonse Thomas Masi; R G Grau; T A Medsger; Virginia D Steen; P J Clements; L Szydlo; W A D'Angelo
Prognostic importance of cardiac arrhythmias in systemic sclerosis.
The American journal of medicine 1988;84(6):1007-15.
1987: James R Seibold; R R Molony; D Turkevich; M C Ruddy; John B Kostis
Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis.
The Journal of rheumatology 1987;14(3):519-24.
1987: A Ohta; J Uitto; A I Oikarinen; R Palatsi; M Mitrane; E A Bancila; James R Seibold; H C Kim
Paraproteinemia in patients with scleredema. Clinical findings and serum effects on skin fibroblasts in vitro.
Journal of the American Academy of Dermatology 1987;16(1 Pt 1):96-107.
1986: M P Mitrane; A Singh; James R Seibold
Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature.
The Journal of rheumatology 1986;13(5):969-72.
1986: James R Seibold; P J Knight; J B Peter
Anticardiolipin antibodies in systemic sclerosis.
Arthritis and rheumatism 1986;29(8):1052-3.
1986: R R Molony; D M MacPeek; P L Schiffman; M Frank; J A Neubauer; M Schwartzberg; James R Seibold
Sleep, sleep apnea and the fibromyalgia syndrome.
The Journal of rheumatology 1986;13(4):797-800.
1986: James R Seibold; C A Terregino
Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
The Journal of rheumatology 1986;13(2):337-40.
1985: James R Seibold; E A Bancila
Fascial elastosis mimicking eosinophilic fasciitis.
The Journal of rheumatology 1985;12(6):1196-8.
1985: C A Terregino; I G Udasin; James R Seibold
Family members of crest patients lack serum anticentromere antibody.
The Journal of rheumatology 1985;12(3):635-6.
1985: James R Seibold; J Uitto; B B Dorwart; D J Prockop
Collagen synthesis and collagenase activity in dermal fibroblasts from patients with diabetes and digital sclerosis.
The Journal of laboratory and clinical medicine 1985;105(6):664-7.
1985: C A Terregino; James R Seibold
Influence of the menstrual cycle on Raynaud's phenomenon and on cold tolerance in normal women.
Angiology 1985;36(2):88-95.
1985: James R Seibold; J N Harris
Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon.
The Journal of rheumatology 1985;12(1):99-103.
1985: James R Seibold
Serotonin and Raynaud's phenomenon.
Journal of cardiovascular pharmacology 1985;7 Suppl 7():S95-8.
1984: R C Gupta; James R Seibold; M R Krishnan; J C Steigerwald
Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis.
Clinical and experimental immunology 1984;58(1):68-76.
1984: Lawrence Friedhofff; James R Seibold; H C Kim; K S Simester
Serotonin induced platelet aggregation in systemic sclerosis.
Clinical and experimental rheumatology 1984;2(2):119-23.
1984: James R Seibold; A H Jageneau
Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
Arthritis and rheumatism 1984;27(2):139-46.
1984: H C Kim; K Klein; S Hirsch; James R Seibold; J Eisele; Parvin Saidi
Arthroscopic synovectomy in the treatment of hemophilic synovitis.
Scandinavian journal of haematology. Supplementum 1984;40():271-9.
1983: AS Janoff; S Carpenter-Green; A L Weiner; James R Seibold; G Weissmann; M J Ostro
Novel liposome composition for a rapid colorimetric test for systemic lupus erythematosus.
Clinical chemistry 1983;29(9):1587-92.
1982: Stephen I Wasserman; James R Seibold; T A Medsger; G P Rodnan
Serum eosinophilotactic activity in eosinophilic fasciitis.
Arthritis and rheumatism 1982;25(11):1352-6.
1982: James R Seibold
Digital sclerosis in children with insulin-dependent diabetes mellitus.
Arthritis and rheumatism 1982;25(11):1357-61.
1982: James R Seibold; G P Rodnan; T A Medsger; A Winkelstein
Circulating immune complexes in eosinophilic fasciitis.
Arthritis and rheumatism 1982;25(10):1180-5.
1982: James R Seibold; T A Medsger; A Winkelstein; R H Kelly; G P Rodnan
Immune complexes in progressive systemic sclerosis (scleroderma).
Arthritis and rheumatism 1982;25(10):1167-73.
1982: James R Seibold; R B Buckingham; T A Medsger; R H Kelly
Cerebrospinal fluid immune complexes in systemic lupus erythematosus involving the central nervous system.
Seminars in arthritis and rheumatism 1982;12(1):68-76.
1982: James R Seibold; H C Kim
Acral vasospasm complicating therapy with ibuprofen and tolmetin.
The Journal of rheumatology 1982;9(4):647-8.
1982: James R Seibold; M C Trontell
Anticentromere antibody and primary pulmonary hypertension.
The Journal of rheumatology 1982;9(4):607-9.
1981: M Rosen; James R Seibold
Osteonecrosis vs transient osteoporosis.
JAMA : the journal of the American Medical Association 1981;245(18):1817.
1981: C J Lynch; G P Rodnan; G Singh; James R Seibold
HLA-A and B antigens in eosinophilic fasciitis.
The Journal of rheumatology 1981;8(2):352-3.
1981: James R Seibold; C J Lynch; T A Medsger
Cholestasis associated with D-penicillamine therapy: case report and review of the literature.
Arthritis and rheumatism 1981;24(3):554-6.
1980: James R Seibold; C J Lynch
Disco lupus: a new disease syndrome.
Arthritis and rheumatism 1980;23(8):962-3.
1980: James R Seibold; L R Wechsler; R J Cammarata
LE cells in intermittent hydrarthrosis.
Arthritis and rheumatism 1980;23(8):958-9.
1980: James R Seibold; R M Iammarino; G P Rodnan
Alpha-1-antitrypsin in progressive systemic sclerosis.
Arthritis and rheumatism 1980;23(3):367-70.
1978: Robert Greenwald; W W Moy; James R Seibold
Functional properties of cartilage proteoglycans.
Seminars in arthritis and rheumatism 1978;8(1):53-67.